Print Page   |   Contact Us   |   Sign In   |   Join iBIO
iBIO Lunch: The Three Rules in Medical Technology
Tell a Friend About This EventTell a Friend
iBIO Lunch: The Three Rules in Medical Technology

Viewing performance through the lens of three straightforward rules can help medical technology companies navigate profound changes in the US health care ecosystem.

When: September 18, 2014
11:30 a.m. - 2 pm
Where: Maggiano's
111 W. Grand Ave.
Chicago, Illinois  60654
United States
Contact: Monique Velasquez

Online registration is closed.
« Go to Upcoming Event List  


Join our speaker, Chas McKhann to discuss the recent changes in the US health care ecosystem are having a profound and transformational impact on the medical technology industry. The Affordable Care Act has catalyzed changes in how med tech customers define value and which stakeholders are involved in decision making. While it has historically been a jewel of American manufacturing—one of the few domestic manufacturing industries that is a net exporter—med tech faces challenges to the legacy business models and strategic choices that these companies have used to excel in the past. More than ever, success requires a clear and consistent focus on delivering differentiated value and performance to customers.

Meet our speaker, Chas McKhann:


Chas McKhann is a Director in Life Sciences at Monitor Deloitte, the strategy consulting practice of Deloitte Consulting, LLP.  Chas and his colleagues help medical technology companies develop and execute growth strategies to thrive in the changing global healthcare marketplace. Chas’s areas of expertise include global commercialization strategies, customer analytics and segmentation, marketing excellence, product launches, and sales force organization & effectiveness.    


Chas’s experience includes a distinctive combination of more than 10 years as a strategy consultant and more than 10 years in executive leadership roles at prominent medical technology companies.  Chas’s prior executive leadership roles include: WW VP of Marketing for the $2.5 billion Cardiac Rhythm Management division at Boston Scientific, General Manager for a $200 million franchise at Guidant, and Director of Marketing at Johnson & Johnson where he oversaw the launch of the CYPHER® drug eluting stent.  Prior to joining Deloitte, Chas was CEO of a VC-funded medical device start-up company. 


Chas earned Bachelor of Arts and a Masters of Business Administration from Stanford University.  He lives in Minneapolis with his wife and two children.



Association Management Software Powered by YourMembership  ::  Legal